LAG3 and neoplasm: The tumor-infiltrating immune cells comprised a previously unrecognized subtype of CD8+ T cells that predominantly expressed the checkpoint marker LAG3, rather than PD-1 and CTLA-4, indicating that LAG-3 would be a potential target in immune checkpoint inhibitors in UM patients (39).